A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

The requested reference [2a5e4d2e88d614fc2f082d17d583b99a65c71e63] no longer exists in our database. It has been replaced by the current reference: [49b22b125223289fbf4e97dd8878837de1c8fb7e]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19. In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
Epistemonikos ID: 7a43bec9c622d93d9d88aaa77cb071f323bb7a1b
First added on: Aug 09, 2023